Allogeneic peripheral blood stem cell transplantation for severe aplastic anemia
Therapeutic Apheresis, vol.5, no.1, pp.54-57, 2001 (Scopus)
- Publication Type: Article / Abstract
- Volume: 5 Issue: 1
- Publication Date: 2001
- Doi Number: 10.1046/j.1526-0968.2001.005001054.x
- Journal Name: Therapeutic Apheresis
- Journal Indexes: Scopus
- Page Numbers: pp.54-57
- Keywords: Allogeneic peripheral blood stem cell transplantation, Severe aplastic anemia
- Yozgat Bozok University Affiliated: No
Abstract
Allogeneic peripheral blood stem cell transplantation- (PBSCT) is rarely applied for the treatment of severe aplastic anemia (SAA) because of questionable durability of engraftment and increased risk of graft versus host disease (GVHD). We performed allogeneic PBSCT in 3 SAA patients from their human leukocyte antigen (HLA)-identical siblings. One received bone marrow after conditioning with cyclophoshamide (Cy) plus antithymocyte globulin. He had a second transplant with peripheral blood stem cells from the original donor because of a graft failure (GF). Two other patients received PBSCT as a first option, with Cy as the only conditioning drug. The 3 patients received short-term methotrexate and cyclosporine as a postgrafting immunosupression. In the latter 2 cases, no GF has been observed, and a successful and complete hematological recovery was achieved and maintained for 28 and 25 months, respectively. In conclusion, PBSCT provides a quick and complete hematological recovery in SAA patients.